Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2008

View Archived Issues

Adoptive transfer of T cells loaded with oncolytic virus effective in eliminating cancer metastasis

Endothelial progenitor cells regulate the angiogenic switch in lung metastasis model

Promising preclinical results of novel broadly neutralizing antibodies against HCV infection

Eisai granted early termination of statutory waiting period in acquisition of MGI

Novel therapeutic agents for hematologic disorders reported in recent patent literature

Adherex initiates phase IIb clinical trial of ADH-1 for melanoma

Senexis secures new funding to develop innovative compounds for AD

Angiotech and Symphony enter licensing agreement for PEG-based biomaterials

Primary endpoint met in phase II trial of 2PX for osteoarthritis

Peptimmune completes first close of series D preferred stock offering

Genaera initiates phase I trial of trodusquemine in overweight and obese diabetic patients

Preclinical characterization of aripiprazole shows uniqueness of D2 partial agonists

Cleveland BioLabs' Protectan CBLB-502 not selected for defense contract award

Diamyd submits application to initiate phase III studies of Diamyd in Sweden

Decreased VLDLR expression may be a biomarker for schizophrenia

Cerepro phase III trial results expected in July 2008

FDA committee to consider two injectable antibiotics from Theravance and J&J

GSK will not option XL-784 for further development

Recent Novartis patent discloses novel antiasthmatic agents

Schering-Plough and Shionogi launch Claritin dry syrup 1%

Motilin receptor agonists described in recent GSK patent

Roche and Ventana sign definitive merger agreement

Promising results for GW cannabinoid treatments for diabetes and metabolic disorders

Progress from Arpida's pivotal phase III trial of TLT treatment in onychomycosis

New treatment option for psoriasis imparted in recent Nippon Shinyaku patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...